Introduction

Studies of IL-10 deficient (IL-10
À/À
) and IL-10 receptor-2 deficient mice show that these mice develop a T helper (Th)-1-mediated intestinal inflammation and indicate that IL-10 is an important regulatory cytokine within the mucosal immune system. 1, 2 The activity of IL-10 in counter regulating mucosal inflammation is likely to be multifactorial. IL-10 is a potent down regulator of IL-12 production and thus acts at the level of Th1 cell induction. 3 In addition, IL-10 suppresses the production of other pro-inflammatory cytokines and chemokines including TNF-a IL-1b, IL-6 and IL-8. 4 Finally, there is substantial evidence that IL-10 acts both to promote the differentiation and augment the activity of regulatory T cells. [5] [6] [7] [8] The observations in IL-10 À/À mice have laid the foundation for therapeutic trials of IL-10 in several other models of colitis. These studies have shown that systemic IL-10 administration is able to prevent intestinal inflammation by down regulating the intestinal pro-inflammatory Th1 response. 1, 9, 10 Based on these successful experimental findings, recombinant (r)IL-10 was administered by subcutaneous injection to patients with either mild/moderate or steroid refractory Crohn's disease, as well as in patients undergoing ileal resection to prevent postoperative recurrence. [11] [12] [13] Although the data indicated that systemic rIL-10 therapy is safe and well tolerated, this therapy resulted in only a modest response in steroid naïve patients, and no significant benefit compared to placebo in steroid refractory patients. Explanations for this lack of efficacy include the short half-life of rIL-10, 14 local delivery of insufficient amounts of rIL-10 to inhibit mucosal Th1 responses and the side effects associated with high-dose rIL-10. 15 Sustained IL-10 delivery may prove more effective than daily systemic injections. Indeed, daily intra-gastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in disease severity in mice with dextran sulphate sodium induced colitis and prevented the onset of colitis in IL-10 À/À mice. 16 Alternatively, adenoviral vectors could be used to deliver the IL-10 gene and secure constant expression of high levels of IL-10 within the gastro-intestinal tract. Adenoviral vectors can infect intestinal epithelial cells with high efficiency 17 and after intravenous administration they target the liver and the spleen, but also the colon. 18, 19 Adenoviral transfer of IL-10 has been shown to be beneficial in murine experimental arthritis, another Th1-mediated disease. [20] [21] [22] Finally, we have recently demonstrated the efficacy of adenovirus-mediated IL-10 gene transfer in the treatment of established colitis in IL-10 À/À mice. 23 In the present study, we have investigated the therapeutic efficacy of mIL-10 adenovirus-mediated (AdvmuIL-10) gene transfer in murine 2,4,6-trinitrobenzene sulphonic acid (TNBS) colitis, which has many histological and immunological similarities to Crohn's disease, and is also relatively unresponsive to daily systemic injections of recombinant IL-10. 24 Intra-rectal TNBS administration induces a transmural colitis, which results from the rapid induction of an IL-12-driven, Th1-mediated response that is not balanced by the prompt appearance of a regulatory response. 25 The TNBS model is associated with increased concentrations of IFN-g and TNF-a in the intestinal mucosa. 26 In this paper we demonstrate that systemic administration of adenovirus expressing mIL-10, but not the control adenovirus or PBS vehicle, reduces both the clinical and histopathological signs of TNBS colitis. These data suggest that adenovirus-mediated gene transfer may be a valuable therapeutic alternative in Crohn's disease.
Results
Biodistribution of IL-10 expression
Intravenous administration of adenoviral vectors predominantly results in transduction of hepatocytes. 18 To confirm that AdvmuIL-10 infection was successful, IL-10 expression was assessed in liver homogenates of BALB/c mice with TNBS colitis treated with 1 Â 10 8 PFU AdvmuIL-10, Adv0 or PBS vehicle (n=5 tested/group, Figure 1 ). The mean IL-10 concentration 10 days after AdvmuIL-10 injection was 760 7 99 pg/mg compared to 331 7 80 pg/mg in PBS (P=0.031) and 224 7 32 pg/mg in Adv0 (P=0.008) treated mice. Ten days after injection, IL-10 (400 (50-1230) pg/ml) was detected in the serum of six out of the 15 surviving mice that had received AdvmuIL-10. In all the other mice, IL-10 levels in the serum were below the detection limit. There were no differences between the groups in the concentration of IL-10 detected in colon homogenates (data not shown).
AdvmuIL-10 treatment reduced body weight loss in TNBS colitis
To determine whether AdvmuIL-10 was able to prevent TNBS colitis, disease was induced in BALB/c mice 24 h after tail vein injection of 1 Â 10 8 PFU of AdvmuIL-10. Control mice with TNBS colitis received Adv0 or PBS alone. There was 25% mortality in each TNBS group. As expected, intra-rectal instillation of TNBS resulted in diarrhoea and wasting in mice treated with PBS and Adv0 ( Figure 2 ). However, recipients of AdvmuIL-10 suffered less severe weight loss and by the end of the experiment, the body weights of AdvmuIL-10-treated mice were significantly higher than PBS-treated (P=0.015) or Adv0-treated mice (P=0.020). All negative control mice that received intra-rectal saline 24 h after systemic injection with PBS, Adv0 or AdvmuIL-10 survived and gained weight throughout the experiment (data not shown). These results indicate that administration of AdvmuIL-10 significantly attenuated body weight loss associated with TNBS-induced colitis.
AdvmuIL-10 diminished both stool and serum markers of inflammation in TNBS colitis Both Crohn's disease and experimental colitis are associated with a profound increase in faecal levels of pro-inflammatory proteins (eg IL-1b and soluble TNFR-II). 23, 27 Therefore, stools collected upon sacrifice were assayed for these cytokines by ELISA ( Figure 3 ). As expected, IL-1b and TNFR-II levels were high in TNBS mice treated with PBS (731 7 348 and 441 7 90 pg/ml, respectively) and undetectable in all saline control mice. In stools of AdvmuIL-10-treated TNBS mice, a reduction in IL-1b level (16.9 7 3 pg/ml) was observed compared to both PBS-(see above, P=0.046) and Adv0-treated TNBS mice (135 7 58 pg/ml, P=0.073). In addition, AdvmuIL-10 treatment significantly decreased TNFR-II levels (160 7 29 pg/ml) compared to both PBS (see above, Po0.001) and Adv0 treatment (279 7 14 pg/ml, Po0.001).
Systemic IL-6 levels and SAP were determined as markers of disease activity in serum samples. AdvmuIL-10 treatment resulted in reduced serum IL-6 levels 
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J Lindsay et al (14.4 7 1.4 pg/ml) compared to PBS (48 7 24 pg/ml, P=0.040) and Adv0 treatment (47 7 25 pg/ml, not significant) in mice with TNBS colitis. As shown in Figure 4 , SAP levels were significantly lower in AdvmuIL-10-treated mice (244 7 23 mg/ml) than in PBS (1162 7 413 mg/ml, Po0.001) and Adv0-treated colitic mice (587 7 141 mg/ml, P=0.004). AdvmuIL-10 did not alter systemic IL-6 or SAP levels in the saline control mice (data not shown). Together, these findings indicate that AdvmuIL-10 therapy diminishes both the local consequences and systemic manifestations of TNBS colitis.
AdvmuIL-10 treatment decreased intestinal inflammation in BALB/c mice with TNBS colitis
Macroscopic signs of inflammation observed in TNBSinduced colitis are marked oedema and mucosal thickening, which are reflected by increased colon weight. 28 Mice were sacrificed on day 10, and the weight of the last 6 cm of the colon was determined. There was a significant increase in the mean colon weight in all groups that received TNBS compared to the corresponding saline control groups irrespective of whether the mice had been treated with PBS (P=0.001), Adv0 (Po0.001), or AdvmuIL-10 (Po0.001). However, colons from mice with TNBS colitis that had received AdvmuIL-10 weighed less (208 7 7 mg) than colons from colitic mice that had received either Adv0 (237 7 13 mg, P=0.038) or PBS vehicle (244 7 22 mg, P=0.080), although this did not reach statistical significance for the latter. TNBS administration results in an acute colitis that is characterized by mucosal ulceration and an influx of inflammatory cells. A pathologist blinded to treatment allocation performed histological analysis of colons harvested from mice in the above experiments ( Figure 5 ). The total histological score was decreased in AdvmuIL-10-treated TNBS mice (7.1 7 0.9) compared to PBS-(10.8 7 1.3, P=0.038) and Adv0-treated TNBS mice (10.4 7 1.0, P=0.012). As illustrated by the pictures in Figure 6 , mice with TNBS colitis that had been treated with AdvmuIL-10 displayed less mucosal ulceration, crypt loss and fibrosis, as well as a diminished influx of polymorphonuclear cells. The colons harvested from saline-instilled mice showed only mild oedema. There were no significant differences in histological scores between PBS-, Adv0-and AdvmuIL-10-treated mice (mean scores 2.0 7 0.7, 0.8 7 0.5 and 1.7 7 1.0 respectively). Thus, AdvmuIL-10 treatment prevented development of severe TNBS colitis.
AdvmuIL-10 treatment decreases colonic cytokine production
To investigate whether the therapeutic efficacy of AdvmuIL-10 treatment was related to a generalized reduction of T cell responsiveness, cells from caudal 
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/CD28 antibodies. IFN-g and TNF-a levels were quantified by ELISA. No significant differences were found in IFN-g and TNF-a concentrations in supernatants of stimulated caudal lymph node and spleen cell cultures harvested from both TNBS and saline control mice treated with PBS, Adv0 or AdvmuIL-10 (data not shown). In contrast, AdvmuIL-10 therapy did affect local pro-inflammatory cytokine release within the colon. IFN-g and IL-6 concentrations in colonic homogenates from AdvmuIL-10-treated TNBS mice (262 7 41 and 172 7 18 pg/ml) were lower than those from TNBS mice treated with PBS (429 7 79 pg/ml, P=0.04 and 1000 7 600 pg/ml, P=0.038) and Adv0 (430 7 118 and 428 7 201 pg/ml, both not significant). TNF-a concentrations were similar in the AdvmuIL-10-and Adv0-treated mice (66 7 9 and 72 7 10 pg/ml), although both were lower than in the PBS-treated mice (160 7 75 pg/ml). These results suggest that AdvmuIL-10 reduced colon inflammation by modulating local production of pro-inflammatory cytokines such as IFN-g and IL-6.
Discussion
The results presented here show that a single systemic dose of AdvmuIL-10 attenuated TNBS colitis. This effect was related specifically to IL-10 transgene expression, since both the empty cassette vector and PBS vehicle were unable to modify the course of disease. Furthermore, AdvmuIL-10 suppressed the inflammatory marker levels in stool samples and colonic homogenates as well as inhibiting the acute-phase response and systemic IL-6 release. As expected, the systemic administration of adenoviral vectors targeted hepatocytes, since high levels of IL-10 were detected in liver homogenates of AdvmuIL-10-treated mice 10 days after administration. In addition, IL-10 was detected in the serum of several mice that had received AdvmuIL-10. This agrees with our previous observation that serum mIL-10 levels are raised for approximately 1 week after AdvmuIL-10 administration in IL-10 À/À mice. 23 Previous studies have demonstrated low-level colonic transgene expression after systemic adenoviral vector delivery; 18, 19 however, there was no difference in the levels of IL-10 detected in colon homogenates from AdvmuIL-10 or control treated mice with TNBS colitis.
The systemic delivery of replication-deficient adenoviral vectors was well tolerated in these experiments. The control virus did not induce an acute phase response nor did it exacerbate intestinal inflammation in either diseased or control mice. In fact, the only effect of Adv0 observed was a non-significant reduction in acutephase response, stool pro-inflammatory protein levels, and colonic homogenate pro-inflammatory cytokine levels compared to PBS-treated controls. This may reflect the functional lymphopenia that has previously been reported after adenoviral administration, which may limit its use in clinical practice. 29 Finally, in this study we did not assess the host anti-adenovirus response, which may shorten the duration of transgenic IL-10 expression. However, in other animal models, we 23 and others 30, 31 have shown that the delivery of immunoregulatory genes is able to suppress the development of antiadenoviral antibodies resulting in extended transgene expression. As in the human clinical trials, 11, 12 previous studies of IL-10 therapy in TNBS colitis have yielded mixed results. Pre-treatment of BALB/c mice with high-dose intraperitoneal murine IL-10 restored the tolerance of lamina propria mononuclear cells to autologous colonic bacterial sonicates, whilst not affecting the proliferative response to heterologous bacterial sonicates. 32 However, the effect of IL-10 on the histological severity of colitis was not reported. A separate study that assessed the effect of daily IL-10 injections on rats with TNBS colitis demonstrated no effect on the histological disease severity even if the IL-10 injections were commenced prior to colitis induction. 24 It is possible that the modest efficacy in both clinical trials and animal models of colitis reflects the short half-life and limited mucosal bio-availability of systemically administered recombinant IL-10. 11 Barbara et al examined the therapeutic efficacy of an adenoviral vector encoding human IL-10 administered by intraperitoneal injection to rats with TNBS colitis. 33 No changes were demonstrated in histological scores when the virus was administered 1 h after colitis induction, although they did demonstrate a slight improvement in colitis if the adenoviral vector was injected 24 h prior to TNBS administration. However, in the latter study the median serum level of IL-10 was only 12 pg/ml, 24 h after injection, compared with 400 pg/ml 1 week after therapy in our study. This difference may reflect the decreased uptake of adenoviral vectors after intraperitoneal compared to intravenous administration. 18 The experiments reported here demonstrate that a single systemic dose of AdvmuIL-10 prior to TNBS administration results in significantly less weight loss and lower histological scores than control virus. We extended the findings of Barbara et al 33 by delineating the effect of IL-10 gene therapy on the cytokine network 
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within the inflamed mucosa. The mechanisms by which the IL-10 induced by AdvmuIL-10 therapy could have diminished disease severity in the intestine include down regulation of antigen presenting cell activity, inhibition of pro-inflammatory cytokine production and activation of regulatory T cells. Our experiments did not address these mechanisms directly. However, there was a clear trend for AdvmuIL-10 therapy to decrease the levels of Th-1 cytokines detected in the colonic mucosa, which suggests an effect on T cell differentiation and cytokine release. The statistical significance of these results was variable (more marked when AdvmuIL-10 was compared to PBS than Adv0 controls); this reflects the wide variation in cytokine release between animals. Importantly, this effect was localized to the mucosa, as AdvmuIL-10 had no effect on the ability of systemic lymphocytes to respond to T cell receptor stimulation. The reduction in mucosal inflammation seen with AdvmuIL-10 therapy in TNBS colitis (quantified as a 34% decrease in histological score) is not as impressive as the reduction seen in IL-10 À/À mice. 23 However, this is not surprising given the breadth of the inflammatory cascade that is activated by TNBS administration, compared to the isolated defect in IL-10 À/À mice. In fact, the results compare favourably with other therapeutic strategies reported in mice with TNBS colitis; for example, IL-18 binding protein (42% fall in histological score) 26 and the chemokine receptor antagonist Met-RANTES (57% fall in histological score). 34 We have recently shown that subcutaneous administration of high-dose rIL-10 may have pro-inflammatory effects via induction of IFN-g. 15 No evidence of this was detected after AdvmuIL-10 therapy, since spleen cell production of IFN-g and TNF-a was not altered, and serum levels of IL-6 were decreased. This discrepancy may be explained by differences in the systemic IL-10 levels achieved and changes in the balance of its immunoregulatory and pro-inflammatory effects. Therapy with recombinant IL-10 requires frequent high-dose administration due to its rapid clearance, whereas AdvmuIL-10 therapy delivers stable IL-10 levels. The pro-inflammatory effects reported by Tilg et al were only observed at high daily doses (20-25 mg/kg) which have been shown to result in peak serum concentrations of 6 ng/ml. 11, 15 In contrast, serum IL-10 could only be detected in six out of the 15 mice treated with AdvmuIL-10 with a median level of 400 pg/ml. Thus, IL-10 gene therapy delivers constant low-level IL-10 that is sufficient to prevent intestinal inflammation, whilst minimizing the pro-inflammatory side effects associated with the high serum levels that occur after systemic injection of the recombinant protein.
However, the systemic administration of AdvmuIL-10 leading to continuous elevated levels of IL-10 may cause some systemic side effects, as shown previously in IL-10 À/À mice. 23 Furthermore, systemic AdvmuIL-10 administration does not deliver specific colonic transgene expression. Thus, in order to minimize exposure of nontarget organs to both the transgene and the adenoviral vector, local gene therapy would be the next step in the development of targeted biological therapy. The rectal administration of adenoviruses with normal fibre, predominantly targets epithelial cells, whereas adenoviruses with a modified fibre structure also infect lamina propria T cells and mononuclear cells. 18 In fact, a recent study has demonstrated that intra-rectal administration of an E1-deleted adenoviral vector expressing IL-18 antisense mRNA inhibits mucosal IFN-g release and suppresses inflammation in the transfer model of colitis. 35 Alternative strategies to reduce the systemic side effects of immunoregulatory gene therapy include the use of lesscommon adenovirus serotypes, 36 or modifications that alter the tropism of the virus. Thus, although this study has demonstrated the benefit of IL-10 gene therapy, further studies are required to determine the most appropriate vector and route of administration.
Immunoregulatory gene delivery offers the prospect of local down regulation of the immune response in Crohn's disease. The results of the present study, which demonstrate that transient overexpression of IL-10 by prior administration of an adenoviral vector prevents TNBS colitis, confirm the therapeutic potential of IL-10 gene therapy in intestinal inflammation.
Materials and methods
Adenoviral vectors
The recombinant E1 deleted type 5 adenovirus encoding murine IL-10 under an RSV promoter (AdvmuIL-10) and the empty cassette adenovirus (Adv0) were a gift from Professor Dallman, Imperial College, London, UK. 23 Viruses were propagated in the 293 human embryonic kidney cell line (Quantum Biotechnology, Montreal, Canada) and purified by ultracentrifugation through two caesium chloride gradients (Boehringer Mannheim, Lewes, UK). The titre of the adenoviral vectors was determined by plaque assay on 293 cells. 37 Viral stocks were aliquoted and stored in 10% glycerol at À801C until use.
Mice and induction of colitis
BALB/c mice were purchased from Charles River (Charles River, Someren, the Netherlands) and maintained in filter-top cages under specific-pathogen-free conditions at our animal care facility. The Animal Studies Ethics Committee of the University of Amsterdam, the Netherlands approved all experiments. The experiments were conducted in 8-week-old female mice. Colitis was induced by rectal administration of 0.5-2 mg TNBS (Sigma Chemical Co, St Louis, MO, USA) dissolved in 40% ethanol (Merck, Darmstadt, Germany), using a vinyl catheter that was positioned 3 cm from the anus, as described previously. 28 Control mice underwent identical procedures, but were instilled with similar volumes of saline (NaCl 0.9%). All mice received two instillations of TNBS/saline separated by 7 days. One day prior to the first instillation of TNBS/saline, mice received a tail vein injection of 1 Â 10 8 PFU of AdvmuIL-10, Adv0 or saline vehicle ( Table 1) .
Assessment of inflammation
Body weights were recorded and wasting disease was determined by percentage of weight loss from initial body weight. Mice were sacrificed 9 days after the first TNBS/saline instillation (ie 48 h following the second TNBS challenge) by cardiac puncture. Serum was separated by centrifugation (10 000 g for 10 min) from IL-10 gene therapy prevents TNBS-induced colitis J Lindsay et al whole blood and stored at À201C until use. The spleen, caudal lymph nodes, liver and colon of each animal were harvested through a midline incision. The colon was opened longitudinally and stools were collected. The wet weight of the distal 6 cm of colon was measured and used as an index of disease-related intestinal wall thickening. Subsequently, each colon was divided longitudinally into two parts: one for histology, the other was snap-frozen in liquid nitrogen and stored at À801C for cytokine measurement. Liver and colon homogenates were made with a tissue homogenizer in 9 volumes of Greenberger lysis buffer (300 mM NaCl, 15 mM Tris, 2 mM MgCl 2 , 2 mM Triton (X-100), Pepstatin A, Leupeptin, Aprotoninie (all 20 ng/ml), pH 7.4). Tissue was lysed for 30 min on ice followed by two times centrifugation (10 min 14 000 g). Homogenates were stored at À201C until further use.
Histological analysis
The longitudinally divided colons were rolled up and fixed in 4% formalin. Fixed tissues were embedded in paraffin, and 4À6 mm sections were stained with haematoxylin and eosin for histological evaluation. An experienced pathologist blinded to treatment allocation scored the following parameters: (1) percentage of colon involved, (2) fibrosis, (3) oedema, (4) erosions and ulcerations, (5) crypt loss, (6) infiltration of mononuclear cells or (7) polymorphonuclear cells as described previously. 26 The total score ranges from 0 (normal colon) to a maximum of 20 points (severe inflammation).
Cell cultures
Cell suspensions of the spleens and caudal and mesenteric lymph nodes were prepared by filtration through a cell strainer (Becton Dickinson) and red cell lysis of splenocyte suspensions. Cells were suspended in RPMI 1640 medium (Biowhittaker, Walkersville, MD, USA) supplemented with 10% FCS and 1% penicillin-streptomycin-glutamine solution (GibcoBRL, Grand Island, NY, USA). Cells (1 Â 10 5 /well) were seeded on 96-well roundbottom plates (Costar) pre-coated with anti-CD3 antibody (1:30 concentration; 145.2C11 clone) in a final volume of 200 ml in the presence of soluble aCD28 monoclonal antibodies (mAb) (1:1000 concentration, Pharmingen, San Diego, CA, USA) under standard conditions (371C, 5% CO 2 ). Culture supernatants were collected from three wells after 48 h, pooled and stored at À201C until use.
Stool samples
Stool samples were collected upon sacrifice from all animals and weighed. Samples were emulsified in 500 ml per 100 mg stool weight of a solution of 1mg/ml soy trypsin inhibitor and 1 mg/ml phenylmethylsulphonyl fluoride in PBS. Supernatants were collected after centrifugation at 10 000 g for 15 min and stored at À201C.
Cytokine analysis and SAP measurement
Cytokine concentrations (IL-10 and TNF-a (BD Pharmingen, San Diego, CA, USA); IFN-g (Genzyme Diagnostics, Cambridge, MA, USA); IL-1b (R&D Systems, Abingdon, Oxon, UK); sTNFR-II (kindly donated by Dr Burman, Mastricht, Germany) and IL-6 (Sandoz, Basel, Switzerland) were measured by sandwich ELISA using paired Abs according to the manufacturer's recommendations. SAP levels were measured in serum samples by ELISA as described previously. 23 
Statistical analysis
Differences between treatment groups were analysed by the Mann-Whitney U test. Results are expressed as mean 7 s.e.m. A two-tailed P-value of less than 0.05 was considered to represent a significant difference. 
